CIBILTECH
Provides a prediction of kidney allograft survival, enabling clinicians to anticipate patient health outcomes, improving medical decisions through personalized treatments.
- B2B
- commission
- health
- health platform
- medical devices
- biotechnology
- artificial intelligence
- big data
- deep tech
- machine learning
- mobile app
- biotechnology
- horizon europe
- dt and ls
- spinout
- core ai
- radar de l'innovation
- ai applications
- tech for business
- eit ecosystem
- ai agents
- eit health
- patient care
- health it
- ai drug discovery
- tech for hospitals and clinics
- tech for medical professionals
- techbio
- physician support tools
- health diagnostics
- hospital
- techbio drug discovery
- clinical decision support
- medical data
- clinical trials
- health information
- mentoring and coaching network (eit health)
- go global (eit health)
- mentoring and coaching network 2020 (eit health)
- bridgehead europe (eit health)
- go global 2019 (eit health)
- bridgehead europe 2020 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | £1.1m | Grant | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | - | 61 % |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | 11 % |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | - | 3 % | 28 % |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Cibiltech is a pioneering company in the healthcare technology sector, specializing in the smart telemonitoring of chronic patients. Their flagship product, Apilife, is a fully connected platform that acts as a medical hub, facilitating seamless communication between patients and their medical teams. This platform supports doctors by providing data-driven, predictive, and personalized information, which aids in making complex medical decisions and improving patient outcomes.
Cibiltech primarily serves healthcare providers, including hospitals and clinics, particularly those involved in nephrology and kidney transplantation. The company operates in the medical technology market, focusing on clinical software solutions that integrate artificial intelligence (AI) to enhance patient care. Their technology is designed to easily integrate with existing hospital systems and daily routines, making it a practical tool for healthcare professionals.
The business model of Cibiltech revolves around the development and deployment of clinical software solutions. They generate revenue through the sale and licensing of their software products, such as the iBox technology, which is used to prevent and treat organ failure using AI. Additionally, their technology can be utilized in designing clinical trials and assessing kidney allograft survival, providing further revenue streams.
Cibiltech has achieved significant recognition, including being named a laureate in the 2020 EIT Health Bridgehead Global program. This accolade underscores their innovative approach and the potential impact of their technology on global healthcare.
In summary, Cibiltech is a forward-thinking company that leverages AI to improve chronic patient care and support medical professionals in making informed decisions. Their solutions are not only innovative but also practical, integrating seamlessly into existing healthcare systems.
Keywords: telemonitoring, chronic patients, AI, nephrology, kidney transplantation, clinical software, predictive analytics, healthcare technology, medical devices, patient outcomes.